Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Mutations in hepatitis C virus genotype 1b and the sensitivity of interferon-ribavirin therapy after liver transplantation.

Fukuhara T, Taketomi A, Okano S, Ikegami T, Soejima Y, Shirabe K, Maehara Y.

J Hepatol. 2010 May;52(5):672-80. doi: 10.1016/j.jhep.2009.10.034. Epub 2010 Mar 4.

PMID:
20346532
2.

Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.

Tong X, Arasappan A, Bennett F, Chase R, Feld B, Guo Z, Hart A, Madison V, Malcolm B, Pichardo J, Prongay A, Ralston R, Skelton A, Xia E, Zhang R, Njoroge FG.

Antimicrob Agents Chemother. 2010 Jun;54(6):2365-70. doi: 10.1128/AAC.00135-10. Epub 2010 Mar 22.

3.

Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors.

Puyang X, Poulin DL, Mathy JE, Anderson LJ, Ma S, Fang Z, Zhu S, Lin K, Fujimoto R, Compton T, Wiedmann B.

Antimicrob Agents Chemother. 2010 May;54(5):1981-7. doi: 10.1128/AAC.01236-09. Epub 2010 Feb 22.

4.

Treatment of chronic hepatitis C using a 4-week lead-in with nitazoxanide before peginterferon plus nitazoxanide.

Rossignol JF, Elfert A, Keeffe EB.

J Clin Gastroenterol. 2010 Aug;44(7):504-9. doi: 10.1097/MCG.0b013e3181bf9b15.

PMID:
20048684
5.

Resistance to direct antiviral agents in patients with hepatitis C virus infection.

Sarrazin C, Zeuzem S.

Gastroenterology. 2010 Feb;138(2):447-62. doi: 10.1053/j.gastro.2009.11.055. Epub 2009 Dec 16. Review.

PMID:
20006612
6.

Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs).

Kieffer TL, Kwong AD, Picchio GR.

J Antimicrob Chemother. 2010 Feb;65(2):202-12. doi: 10.1093/jac/dkp388. Epub 2009 Nov 10. Review.

7.

The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation.

Elazar M, Liu M, McKenna SA, Liu P, Gehrig EA, Puglisi JD, Rossignol JF, Glenn JS.

Gastroenterology. 2009 Nov;137(5):1827-35. doi: 10.1053/j.gastro.2009.07.056. Epub 2009 Aug 4.

PMID:
19664635
8.

Thiazolides: a new class of antiviral drugs.

Rossignol JF.

Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):667-74. doi: 10.1517/17425250902988487. Review.

PMID:
19442032
9.

Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin.

Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB.

Gastroenterology. 2009 Mar;136(3):856-62. doi: 10.1053/j.gastro.2008.11.037. Epub 2008 Nov 19.

PMID:
19135998
10.

Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.

Korba BE, Elazar M, Lui P, Rossignol JF, Glenn JS.

Antimicrob Agents Chemother. 2008 Nov;52(11):4069-71. doi: 10.1128/AAC.00078-08. Epub 2008 Aug 18.

11.

Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796.

Howe AY, Cheng H, Johann S, Mullen S, Chunduru SK, Young DC, Bard J, Chopra R, Krishnamurthy G, Mansour T, O'Connell J.

Antimicrob Agents Chemother. 2008 Sep;52(9):3327-38. doi: 10.1128/AAC.00238-08. Epub 2008 Jun 16.

12.

Effects of mutagenic and chain-terminating nucleotide analogs on enzymes isolated from hepatitis C virus strains of various genotypes.

Heck JA, Lam AM, Narayanan N, Frick DN.

Antimicrob Agents Chemother. 2008 Jun;52(6):1901-11. doi: 10.1128/AAC.01496-07. Epub 2008 Apr 7.

13.

The serine protease domain of hepatitis C viral NS3 activates RNA helicase activity by promoting the binding of RNA substrate.

Beran RK, Serebrov V, Pyle AM.

J Biol Chem. 2007 Nov 30;282(48):34913-20. Epub 2007 Oct 5. Erratum in: J Biol Chem. 2008 Feb 29;283(9):5971.

14.

Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication.

Korba BE, Montero AB, Farrar K, Gaye K, Mukerjee S, Ayers MS, Rossignol JF.

Antiviral Res. 2008 Jan;77(1):56-63. Epub 2007 Sep 4.

PMID:
17888524
15.

Analysis of the domain interactions between the protease and helicase of NS3 in dengue and hepatitis C virus.

Rosales-León L, Ortega-Lule G, Ruiz-Ordaz B.

J Mol Graph Model. 2007 Jan;25(5):585-94. Epub 2006 May 11.

PMID:
16762573
16.

The hepatitis C virus 3'-untranslated region or a poly(A) tract promote efficient translation subsequent to the initiation phase.

Bradrick SS, Walters RW, Gromeier M.

Nucleic Acids Res. 2006 Mar 1;34(4):1293-303. Print 2006.

17.

Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease.

Perni RB, Almquist SJ, Byrn RA, Chandorkar G, Chaturvedi PR, Courtney LF, Decker CJ, Dinehart K, Gates CA, Harbeson SL, Heiser A, Kalkeri G, Kolaczkowski E, Lin K, Luong YP, Rao BG, Taylor WP, Thomson JA, Tung RD, Wei Y, Kwong AD, Lin C.

Antimicrob Agents Chemother. 2006 Mar;50(3):899-909.

18.

Hepatitis C virus nonstructural protein 5A (NS5A) is an RNA-binding protein.

Huang L, Hwang J, Sharma SD, Hargittai MR, Chen Y, Arnold JJ, Raney KD, Cameron CE.

J Biol Chem. 2005 Oct 28;280(43):36417-28. Epub 2005 Aug 25.

19.

Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay.

Ludmerer SW, Graham DJ, Boots E, Murray EM, Simcoe A, Markel EJ, Grobler JA, Flores OA, Olsen DB, Hazuda DJ, LaFemina RL.

Antimicrob Agents Chemother. 2005 May;49(5):2059-69.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk